GlassScriptPhysician profile
Kriya Patel
NPI 1598109522
$1,925.30
in general payments reported to CMS, 2019-2025
17 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.50 · 2023: $272 · 2024: $908 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.73 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $365.38 | 2023-2025 | |
| Pfizer INC. | $192.01 | 2024-2025 | |
| Lilly USA, LLC | $187.49 | 2022-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $177.39 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $126.39 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $95.33 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $78.24 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $68.58 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $62.39 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $60.51 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $52.87 | 2024-2025 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $19.69 | 2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $17.64 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.84 | 2024 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $15.19 | 2024 | Gardasil 9, Capvaxive, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kriya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.